<DOC>
	<DOCNO>NCT00700297</DOCNO>
	<brief_summary>Colchicine first use Behcet 's Disease ( BD ) , 1977 . There controversial report efficacy Colchicine BD . For expert unresponsiveness patient could explain genetic difference Silk Road BD sporadic BD part world . To test hypothesis ( inefficacy colchicine Silk Road BD ) , design randomize double-blind control crossover study Iran , middle Silk Road , second high prevalence BD world .</brief_summary>
	<brief_title>Colchicine Randomized Double-Blind Controlled Crossover Study Behcet 's Disease</brief_title>
	<detailed_description>Patients : They select consecutive patient . The entry criterion : age 14 60 year , confirm diagnosis Behcet 's Disease , absence major organ involvement ( eye , brain , lung , cardio-vascular involvement ) , least one active symptom , treatment least one month . Patients explain study design give sign write consent . During two phase study , major organ involvement appear , patient move study . All patient fulfil new International Criteria Behcet 's Disease . Method : patient randomize study entry take either colchicine placebo . At 4 month , cross . Those take colchicine go placebo placebo go colchicine . Each patient try therefore , colchicine placebo . The primary outcome effect colchicine disease activity index , IBDDAM ( 16-17 ) . To calculate overall IBDDAM baseline , IBDDAM last 12 month ( prior study ) manifestation calculate add together . The overall disease activity index divide number month ( 12 month ) mean activity index per month . IBDDAM measure every 2 month ( middle end , arm study ) . The total IBBDAM 4 month divide 4 mean activity index per month . The secondary outcome see individual symptom respond colchicine ( IBDDAM manifestation ) . Statistical analysis : The analysis do intention treat method . As difference IBDDAM treatment normal distribution Student T test pair sample use evaluate outcome colchicine placebo group . As Levene 's test show homogeneity variance , ANOVA ( one way ) use test effect treatment ( colchicine placebo ) gender patient ' outcome . The dependent variable difference IBDDAM ( treatment ) . The independent variable treatment , gender . SPSS 15 use statistical calculation .</detailed_description>
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Patient 's fulfilled International Criteria Behcet 's Disease . major organ involvement Hypersensitivity reaction</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Oral aphthosis</keyword>
	<keyword>Genital aphthosis</keyword>
	<keyword>Psuedofolliculitis</keyword>
	<keyword>Erythem nodusom</keyword>
	<keyword>Joint manifestation</keyword>
	<keyword>Colchicine</keyword>
</DOC>